Sana Meah
Endocrinology, Diabetes & Metabolism · Munster, INNPI 1043518244
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.4% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Eli Lilly accounts for 89.1% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $11,045, more than ten times the $956 reported in 2019.
Across 58 payments — averaging $211.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$11K
- Novo Nordisk$367
- AstraZeneca$355
- Lilly USA, LLC$173
- Dexcom, Inc.$80
- Mannkind Corporation$77
- plus $286 from 11 others
Across 53 payments — averaging $15,418 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$252K
- Pfizer$211K
- Eli Lilly$140K
- Astrazeneca UK Limited$111K
- Invivyd Inc$67K
- Amgen$31K
- plus $6K from 1 others
What the payments were for
- Travel & lodging$9388%
- Food & beverage$11,34392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 10 | $10,942 |
| Novo Nordisk | 5 | $367 |
| AstraZeneca(2 entities) | 10 | $355 |
| Lilly USA, LLC | 5 | $173 |
| Dexcom, Inc. | 6 | $80 |
| Mannkind Corporation | 4 | $77 |
| Electromed, Inc. | 3 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| IBSA Pharma Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $28 |
| Shire North American Group Inc | 2 | $26 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| Insulet Corporation | 1 | $22 |
| AbbVie | 1 | $18 |
| Philips North America LLC | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,281 in reported general payments places this provider in the 80th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Other endocrinology, diabetes & metabolism in Munster
- Nabeel JabriMunster$11K
- Thottathil GopanMunster$8K
- Maali MilhemMunster$5K
- Milli GuptaMunster$4K
- Nirmal NairMunster$3K
- Ali Al KhazaaliMunster$3K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.